Bryant Furlow

Patients undergoing allo-HSCT can remain immune-impaired for several years after treatment, but methods such as adopting guideline-driven tracking tools to determine which patients have been assessed for immunization eligibility can improve vaccination rates, suggest a feasibility study at ONS.

Delivering vincristine via mini-IV drip bags instead of pushing it with a syringe might avoid injection into spinal fluid, which is uniformly fatal.

The FDA has sent warning letters to 14 companies marketing dozens of unapproved “miracle cure” products online with fraudulent claims that they prevent or cure cancer.

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

Breast conservation therapy is usually best for local treatment for stage II breast cancer-and biology, as well as stage, drives patient outcomes.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma-cancers in which immunotherapy have shown particular promise-breast cancers are nevertheless immunogenic.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.

Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.

Timing remains an important challenge for breast reconstruction in patients undergoing radiation therapy and surgery for breast cancer.

Recent findings have raised doubts about the promise of whole-brain radiation therapy against metastatic brain tumors for patients with advanced breast cancer.

Breast surgeons can and should provide genetic counseling to their patients because the need outstrips the availability of genetic counselors.

Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.

Dacomitinib induction therapy has shown activity in HPV-negative, locally advanced or metastatic penile squamous cell carcinoma.

Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

A single cycle of adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy might reduce recurrence rates for nonseminomatous or combined germ cell tumors of the testis.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.

The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.

Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma.

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

“Liquid biopsy” analyses of circulating tumor DNA from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer, and might point the way for development of new targeted treatments.

Epigenetic lesions, and not just genetic mutations, can cause brain cancer, and one important implication of that observation is that precision-medicine genetic and genomic tools will miss epigenetic lesions that may drive tumor growth or drug resistance.

IDH1-mutant gliomas can affect adjacent, nonmalignant cells in ways that trigger seizures, according to research reported at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology.

Computer analysis of subvisual data extracted from routine clinical MRI exams outperforms human experts at differentiating brain tumor recurrence from radiation necrosis.

Four years in the making, the new 2016 World Health Organization Classification of Tumors of the Central Nervous System includes new genetically identified entities and variants, allowing more diagnostic precision, and a new “layered” approach to diagnosis.

Caring for patients with brain tumors can have marked effects on the well-being of oncology clinicians, frequently leading to burnout, and authors of an ongoing survey study aim to get a clearer picture of those impacts.

The anti-inflammatory ibudilast shows early preclinical promise against glioblastoma cell lines when combined with temozolomide, according to new research.

Several FDA-approved anti-malarial and anti-fungal drugs might be able to overcome a previously unexploited mechanism that allows some leukemia cells to escape programmed cell death.